Breast Cancer Research and Treatment 2001: Vol 65 Index

7 Pages·2001·1 MB·English

Breast Cancer Research and Treatment 65: 263-264, 2001
©) 2001 Kluwer Academic Publishers. Printed in the Netherlands.
Author index, Volume 65
Abouezzi, Z., 225 Goldstein, N., 259 Muchmore, D.B., 125
Akechi, T., 195 Gomez, D.E., 93 Nanjia-Makker, P., 41
Alexander, M., 267 Hebert, J.R., | Nesland, J.M., 23
Alonso, D.F., 93 Heppner, G., 41 Ng, K.W., 125
Andrulis, I.L., 111 Heppner, G.H., 101 Nicholson, R.I., 135
Ariga, N., 31 Ho, G.H., 225 Nicholson, R.1., 155
Arneson, N.C.R., 111 Homma, K., 249 NiezabitowskiA,. , 7 4
Asch, B.B., 11 Hrushesky, W., 217 Nishikawa, T., 203
Asch, HAL... 1 Hyland, A., 11 Norton, L., 125
Berner, H.S., 23 Imoto, S., 195 Onyiiksel, H., 49
Biganzoli, E., 71 Isaksson, E., — Odlind, V., 163
Bisogna, M., 225 Jackson, J.S.. Okuyama, T., 195
Blamey, R.W., 155 Jordan, V. C. 1. Olivero, O.A., 93
Blanco-Sequeiros, G., 55 Kameoka, S., 20: Olivotto, I.A.,
Bonoldi, E., 71 Karasik, A., 12° Peinado, M., 17
Boracchi, P., 71 Kasajima, T., 7 20: Pinder, S.E., i
Borgen, P.I., 225 Kato, T., 203 Paakk6, P., 55
Briand, P., 179 Kenny, F.S., 135 Powles, T.J.,
Burack, R.C., 63 Kimura, T., 203 Puerto, C.d.,
Calvano, J.E., 225 Kobayashi, S., 249 Purdie, D.W.,
Carlstrém, K., 163 Kowalska, T., 77 Rallo, L., 119
Cauley, J.A., 125 Kruczak, A., 77 Redston, M., 111
Cheung, K.L., 155 Krueger, K.A., 125 aa vig7
Cord6n-Card6C,. , 225 Lackowska, B., 77 Retsky, M., 217
Costa, A., 125 Lederman, G., 145 SS EER, I:
Csemiczky, G., 163 Lippman, M.E., 125 Robertson, J.F.R., 155
Dagar, S., 49 Longcope, C., | Rubinstein, I., 49
Dawson, P.J., 101 Lykkesfeldt, A.E., 179 Rys, J., 77
Demicheli, R., 217 Malfair Taylor, S.C., 233 Sagerman, P., 241
Dews, P., 63 Markiewicz, D., 77 Sano, M., 249
Done; S.J., 111 Manas, S., 171 Santner, S.J., 101
BCketts 5. b25 Mates, D., 233 Sasano, H., 31
Edge, S.B., |] Mellstrom, D., 125 Schmitt, H., 125
Eliason, J., 101 Milla, L., 119 Schoultz, B.v., 163
Ellis, 1.0., 135 Milla-Santos, A., 119 Schoultz, E.v., 163
Escobedo, A., 171 Miller, F.R., 101 Sédderqvist, G., 163
Fabra, A., 171 Mitus, J., 77 Sekosan, M., 49
Fanelli, M., 71 Méndez, O., 171 Shekhar, P.V. M., 41
Farrerons, J., 125 Mohamed, A.N., 101 Shiina, M., 249
Fine, M., 145 Moncrease, A., 63 Sierra, A., 171
Fowke, J.H., 1 Morabito, A., 71 Silfen, S.L.,. 125
Gasparini, G., 7] Moreno, A., 171 Simon, M.S., 63
Gee, J.M.W., 135 Moriya, T., 31 Skoog, L., 163
Gimotty, P.A., 63 Morrow, M., 125 Smith, F.B., 241
264 Author index, Volume 65
Solano, V., 119 Tejera, A.M., 93 Willsher, P.C., 135
Soule, H.D., 101 Trevisan, C.H., 233 Winston, J.S., 11
Stepan, J.J., 125 Turpeenniemi-Hujanen, T., 55 Wolman, S.R., 101
Sugawara, A., 31 Uchitomi, Y., 195 Wronski, M., 145
Suzuki, T., 31 Uematsu, T., 249 Yamawaki, S., 195
Tait, L., 101 Visscher, D.W., 41 Zee, KSI.V., 225
Takabayashi, H., 31 Wai, E.S., 233 Ozcelik, H., 111
Talvensaari-Mattila, A., 55 Walls, E.L., 125 Zhang, P.J., 11
Be Breast Cancer Research and Treatment 65: 265-268, 2001.
C) 2001 Kluwer Academic Publishers. Printed in the Netherlands.
Subject index, Volume 65
accelerated relapse receptors in benign breast and cancer
premenopausal status in node-positive breast cancer 241-247
217-224
adjustment disorder Canadian health system
psychiatric morbidity among breast cancer patients health system costs of metastatic breast cancer
195-202 233-240
adjuvant endocrine therapy carcinogenesis
ER in selection 155-162 in vitro model 179-187
advanced breast cancer carcinoma
phase III randomized trial of toremifene vs downregulation of gelsolin 11-21
tamoxifen 119-124 CD44
angiogenesis in infiltrating lobular carcinoma 23-29
node-negative breast cancer 203-215 cell cycle regulation
apoptosis p1448F_hdm2-p53 pathway in breast carcinoma
loss through microsatellite instability 171-177 225-232
reduction of tumorigenicity by AZT treatment cell line
93-99 in vitro model of human breast carcinogenesis
atypical ductal hyperplasia 179-187
gelsolin in breast lesions 11-21 chemical carcinogenesis
atypical hyperplasia VIP receptors in MNU-induced breast cancer in rats
tamoxifen and MCFIOAT xenografts 41-47 49-54
AZT child
reduction of tumorigenicity 93-99 psychiatric morbidity among breast cancer patients
195-202
bel-2 concerns
change in expression on primary tamoxifen psychiatric morbidity among breast cancer patients
135-144 195-202
behavioral intervention coping
effect of patients reminders on mammography psychiatric morbidity among breast cancer patients
screening 63-70 195-202
bias
diet and estrogen metabolism 1-10 DCIS
biomarker p53 protein accumulation in non-invasive lesions
diet and estrogen metabolism 1-10 111-118
blood vessel invasion depression
node-negative breast cancer 203-215 psychiatric morbidity among breast cancer patients
brain metastasis 195-202
fractionated radiosurgery 145-154 diagnostic X-ray
breast-conserving surgery accuracy for measuring extent of candidates for
accuracy for measuring extent of candidates breast conserving surgery 249-257
249-257 diet
helia! CT of the breast 249-257 and estrogen metabolism 1-10
breast tissue in healthy postmenopausal women __ 1-10
266 Subject index, Volume 63
economic costs HDM2
of metastatic breast cancer 233-240 pl4 ARF _ p53 pathway in breast carcinoma
endocrine response 225-232
change in expression on primary tamoxifen helical CT
135-144 accuracy for measuring extent of candidates for
in selection for adjuvant endocrine therapy breast conserving surgery 249-257
155-162 hormone receptors
epigenetic in benign breast and cancer 241-247
in vitro model of human breast carcinogenesis human
179-187 in vitro model of human breast carcinogenesis
epidermal growth factor 179-187
in vitro model of human breast carcinogenesis MCFIOCAI malignant variants from MCFIOAT
179-187 cells 101-110
epithelial proliferation hyperplasia
effects of oral contraceptives 163-169 p53 protein accumulation in non-invasive lesions
ER 111-118
change in expression on primary tamoxifen
135-144 image cytometry
in selection for adjuvant endocrine therapy receptors in benign breast and cancer 241-247
155-162 immunohistochemistry
estrogen metabolism CD44 isoforms in infiltrating lobular carcinoma
and diet 1-10 23-29
in healthy postmenopausal women — 1-10 retinoid receptors in human breast carcinoma
in vitro model of human breast carcinogenesis 31-40
179-187 induced angiogenesis
retinoid receptors in human breast carcinoma premenopausal status accelerates relapse in node-
31-40 positive breast cancer 217-224
estrogen receptor infiltrating lobular carcinoma
in vitro model of human breast carcinogenesis CD44 isoforms 23-29
179-187
levonorgestel
family effects of oral contraceptives on breast epithelial
psychiatric morbidity among breast cancer patients proliferation 163-169
195-202
mammography
family history
effect of patients reminders 63-70
diet and estrogen metabolism 1-10
MCFI10
fluorescence microscopy 49-54
MCFIOCAI malignant variants 101-110
Fluo-VIP
menopause
in MNU-induced breast cancer in rats
continued breast cancer risk reduction: 4-year
49-54
results from the MORE trial 125-134
fractionated radiosurgery
metastasis
for brain metastasis 145-154
MCFIOCAI malignant variants from MCFIOAT
fybrocystic change
101-110
tamoxifen and MCFIOAT xenografts
microsatellite instability associated with the loss of
41-47
apoptosis 171-177
tumor dormancy 71-75
gelatinase A
microsatellite instability
MMP-2 and antiestrogen adjuvant therapy
associated with the loss of apoptosis 171-177
55-61
microvessel density
gelsolin
node-negative breast cancer 203-215
in breast lesions 11-21
Subject index, Volume 63 267
MORE trial prognosis
continued breast cancer risk reduction 125-134 MMP-2 and antiestrogen adjuvant therapy
mutation positive cases 55-61
p53 protein accumulation in non-invasive lesions of proliferative activity and DNA content 77-85
111-118 prognostic factors
MMP-2 and antiestrogen adjuvant therapy 55-61
neuropeptides progression
in MNU-induced breast cancer in rats 49-54 MCFIOCAI malignant variants from MCFIOAT
N-methyl nitrosourea 101-110
inrats 49-54 proliferation
VIP receptors 49-54 prognostic evaluation and DNA content 77-85
node-negative breast cancer p-53 protein
angiogenesis and blood vessel invasion as pro- accumulation in non-invasive lesions 111-118
gnostic indicators 203-215
node-positive carcinoma raloxifene
tumor dormancy 71-75 continued breast cancer risk reduction: 4-year res-
ults from the MORE trial 125-134
oral contraceptives randomized controlled trial
effects on breast epithelial proliferation 163-169 effect of patients reminders on mammography
osteoporosis screening 63-70
continued breast cancer risk reduction: 4-year res- of tamoxifen vs toremifene 119-124
ults from the MORE trial 125-134 RAR
PACAP in human breast carcinoma 31-40
VIP receptors in MNU-induced breast cancer in rats retinoids
49-54 in human breast carcinoma 31-40
palliative care RXR
health system costs of metastatic breast cancer in human breast carcinoma 31-40
233-240
pis’ screening
hdm2-p53 pathway in breast carcinoma 225-232 psychiatric morbidity among breast cancer patients
phyllodes tumor 195-202
prognostic evaluation of proliferative activity and screeni ng controversy
DNA content 77-85 accelerates relapse in node-positive breast cancer
positive hormonal receptors 217-224
phase III randomized trial of tamoxifen vs secretin
toremifene 119-124 VIP receptors in MNU-induced breast cancer in rats
postmenopausal 49-54
phase III randomized trial of tamoxifen vs senescence
toremifene 119-124 reduction of tumorigenicity by AZT treatment
premalignant 93-99
MCFIOCAI malignant variants from MCFIOAT SERM
101-110 continued breast cancer risk reduction: 4-year res-
premenopausal status ults from the MORE trial 125-134
accelerates relapse in node-positive breast cancer STAR trial
217-224 continued breast cancer risk reduction: 4-year res-
primary tamoxifen ults from the MORE trial 125-134
change in expression of ER, bel-2 and MIB! survival
135-144 MMP-2 and antiestrogen adjuvant therapy 55-61
progestogen
effects of oral contraceptives on breast epithelial tamoxifen
proliferation 163-169 and MCFIOAT xenografts 41-47
268 Subject index, Volume 63
continued breast cancer risk reduction: 4-year TP53
results from the MORE trial 125-134 p1448F_hdm2 pathway in breast carcinoma
phase III randomized trial vs toremifene 119-124 225-232
targeting type IV collagenase
VIP receptors in MNU-induced breast cancer in rats MMP-2 and antiestrogen adjuvant therapy
49-54 55-61
telomerase
reduction of tumorigenicity by AZT treatment vasoactive intestinal peptide
93-99 in MNU-induced breast cancer in rats 49-54
three-dimensional image
accuracy for measuring extent of candidates for xenograft mode!
breast conserving surgery 249-257 MCFIOCAI malignant variants from MCFIOAT
toremifene 101-110
phase III randomized trial vs tamoxifen 119-124 of tamoxifen suppression 41-47